Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
1.030
-0.020 (-1.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Should Investors Buy the Dip With Bluebird Bio Stock?
April 06, 2023
The case for buying the dip isn't exactly a slam dunk.
Via
The Motley Fool
1 Small-Cap Stock That Could Soar in 2023
April 02, 2023
Investors should think twice before initiating a position.
Via
The Motley Fool
Why Bluebird Bio Stock Is Sinking This Week
March 30, 2023
A potential regulatory delay is weighing on the biotech's stock this week.
Via
The Motley Fool
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
April 13, 2023
Via
Benzinga
Nasdaq Surges 100 Points; US Producer Prices Drop In March
April 13, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 33,650.06 while the...
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
April 13, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
April 06, 2023
Both biotechs are aiming for the same markets, but they are not equally risky.
Via
The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
April 06, 2023
Neither stock is a good choice for those who can't handle a lot of risk.
Via
The Motley Fool
Analyst Ratings for bluebird bio
March 30, 2023
Via
Benzinga
bluebird bio Earnings Perspective: Return On Capital Employed
March 30, 2023
Via
Benzinga
Why Bluebird Bio Shares Are Plunging Today
March 29, 2023
Via
Benzinga
bluebird bio Earnings Preview
March 28, 2023
Via
Benzinga
S&P 500 Up 1%; Bluebird Bio Shares Plummet
March 29, 2023
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Wednesday. The Dow traded up 0.74% to 32,632.35 while the NASDAQ rose 1.51% to 11,893.07. The S&P 500, also...
Via
Benzinga
Stocks Rise As Investors Bet On Bank Recovery
March 29, 2023
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror.
Via
Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 29, 2023
Via
Benzinga
Nasdaq Rises 1%; US Pending Home Sales Increase In February
March 29, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.58% to 32,580.89 while the NASDAQ rose 1.09% to 11,843.85. The S&P...
Via
Benzinga
UniFirst, Progress Software, SomaLogic And Other Big Stocks Moving Lower On Wednesday
March 29, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Analyst Expectations for bluebird bio's Future
March 07, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
January 24, 2023
Via
Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 29, 2023
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million.
Via
Benzinga
US Stocks Open Higher, Dow Jumps Over 200 Points
March 29, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.72% to 32,628.42 while the NASDAQ rose 1.33%...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 29, 2023
Via
Benzinga
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
March 22, 2023
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.
Via
Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
March 10, 2023
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
March 07, 2023
Via
Benzinga
1 Beaten-Down Stock That Has a Lot to Prove in 2023
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
Skechers To Rally 40%? Here Are 10 Other Analyst Forecasts For Monday
January 23, 2023
Credit Suisse raised the price target for Exelon Corporation (NASDAQ: EXC) from $42 to $46. Credit Suisse analyst Nicholas Campanella maintained an Outperform rating. Exelon shares fell 0.1% to $42.32...
Via
Benzinga
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
January 22, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.